NEW YORK, May 19, 2026, 08:11 EDT
- WGRX traded at $0.14 before the bell, dropping 21.1%. The stock ended Monday at $0.17, up 107.8%, according to Investing.com.
- Wellgistics will post first-quarter earnings after the bell Tuesday, according to a company filing.
- The company withdrew its preliminary proxy materials as it looks at possible strategic deals.
Wellgistics Health fell in premarket trading Tuesday, pulling back after a big jump Monday. Investors looked ahead to the company’s Q1 earnings, but also reacted to a late report, pulled proxy documents and an ongoing strategic review that hasn’t revealed much yet.
The Nasdaq-listed stock traded at $0.14 in premarket as of 8:06 a.m. EDT, dropping 21.1% from Monday’s close. The shares had closed the prior session at $0.17, which was up 107.8%. Premarket is before the regular session, and moves can be bigger when volume is light. Regular hours on Nasdaq are 9:30 a.m. to 4 p.m. Eastern.
Wellgistics is set to post first-quarter 2026 results after the bell. The company said back on May 15 it would put out the numbers on Tuesday. Wellgistics calls itself a healthcare technology and pharmaceutical distributor, connecting over 6,500 pharmacies and upwards of 200 manufacturers.
Another issue is that Wellgistics filed a notice saying it wouldn’t meet the deadline for its 10-Q quarterly report, the regular filing U.S. public companies make. The company said it needed more time for its financial statements and disclosures and planned to file within the five-day extension.
Wellgistics asked the U.S. Securities and Exchange Commission on Monday to pull a preliminary proxy statement it filed May 14. The proxy statement is meant for a shareholder vote. The company said it is not moving forward with those materials as they stand right now, as it looks at possible strategic deals. No final proxy documents have gone out, Wellgistics said.
Wellgistics shares jumped in volatile trading a few days after the company announced it signed a non-binding letter of intent to buy WellCare Today. The deal outline, not a binding contract, puts the possible transaction at about $15 million. Under the plan, $3 million would be paid in cash and the rest in preferred stock under an earnout tied to performance. Preferred stock can have different rights than common shares.
WellCare Today is in chronic care management, remote patient monitoring and remote therapeutic monitoring. Remote monitoring collects patient health data from outside clinics. Chronic care management covers coordinated support for long-term illness. Wellgistics said it plans to use Samsung Galaxy Watch devices in the system and may link with its network of pharmacies. The company said reimbursements and a final deal aren’t certain.
Wellgistics keeps working to move past basic distribution. In a May 13 statement on a Kare PharmTech pilot, Prashant Patel, the company’s president and CEO, said pharmacy engagement and provider connectivity is “a significant opportunity to improve patient outcomes.” Kare PharmTech founder and CEO Mital Panera said it’s about “care coordination and reimbursement workflows.” Stock Titan
Competition is tough. Wellgistics said in its annual filing that it deals with heavy competition in pharmacy, digital pharmacy, clinical concierge, and wholesale drug services. That includes PBMs, retail chains, independents, digital pharmacies, and bigger groups with more money. The company listed digital players like Roman, Lemonaid Health, TruePill, and Amazon’s PillPack in the filing.
Nasdaq futures dropped early Tuesday as U.S. stock futures retreated. Weak chips and new inflation jitters kept risk appetite low, according to Reuters.
The risks stand out. If the Q1 update comes in with soft revenue, bigger cash burn or a slip in filings, shares could give back Monday’s gains. There’s also the chance the strategic review doesn’t bring a deal, and the WellCare Today LOI could shift or fall apart. Wellgistics flagged that financing, approvals, reimbursement, integration, and provider adoption might not happen.
